2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2311

Effect of TNF Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate
Abstract Number: 2312

Spontaneous Vertebral Fractures after Denosumab Discontinuation
Abstract Number: 2313

The Efficacy of Denosumab for Prevention of Osteoporotic Fractures in Patients with Connective Tissue Diseases Receiving Very High Doses of Glucocorticoid
Abstract Number: 2314

Ratio of BMI to BMD at Different Sites and Association with Fragility Fractures
Abstract Number: 2315

Opportunistic Screening for Osteoporosis Using Thoraco-Abdomino-Pelvic Computed Tomography Assessing the Vertebral Density in Rheumatoid Arthritis Patients
Abstract Number: 2316

Errors and Discrepancies in DXA Scans in Imaging Centers in Ecuador
Abstract Number: 2317

Characterization of Paget´s Disease of Bone Patients from the South of Portugal (Algarve and Alentejo) – Clinical and Genetic Aspects
Abstract Number: 2318

Fracture Liaison Service in an Open Health System: Outcomes and Challenges
Abstract Number: 2319

Adherence to Guideline Recommendations for Screening and Treatment of Glucocorticoid Induced Osteoporosis in Patients with Rheumatoid Arthritis on Long Term Glucocorticoid Therapy at a Tertiary Care Center
Abstract Number: 2320

Multimorbidity Is Associated with Hip Fractures in Both Women and Men and across Different Races
Abstract Number: 2321

Dickkopf-1 Serum Levels in Patients with Systemic Sclerosis and Correlation with Trabecular Bone Score
Abstract Number: 2322

Intervals of Bone Mineral Density Measurement during Treatment for Osteoporosis in Patients with Rheumatoid Arthritis
Abstract Number: 2323

Predictors of Mortality in Patients with Hip Fragility Fracture
Abstract Number: 2324

Predictors of Refracture in Patients with Hip Fragility Fracture
Abstract Number: 2325

Sex Differences in the Association of Frailty and Bone Mineral Density in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].